Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P. Lyon, Peter D. Senter, Tim D. Bovee et al.|Nature Biotechnology|2015Cited by 521
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugatesRobert P. Lyon, Peter D. Senter, Tim D. Bovee et al.|Nature Biotechnology|2014Cited by 445
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancersLeia M. Smith, P. J. Carter, Albina Nesterova et al.|British Journal of Cancer|2008Cited by 289
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation TechnologyScott C. Jeffrey, Peter D. Senter, Patrick Burke et al.|Bioconjugate Chemistry|2013Cited by 246
Development of orally active inhibitors of protein and cellular fucosylationNicole M. Okeley, Peter D. Senter, Stephen C. Alley et al.|Proceedings of the National Academy of Sciences|2013Cited by 189